Hanmi’s Roll Continues With ZAI China Cancer Deal
This article was originally published in PharmAsia News
Hanmi is continuing to reap big dividends this year from its original R&D efforts. Following a major licensing out deal with Boehringer Ingelheim for a novel lung cancer therapy in July, the South Korean firm has now reached an additional licensing agreement for the therapy with ZAI Lab for China, Hong Kong and Macau, in a deal that will bolster the Chinese biopharma's growing oncology portfolio.
You may also be interested in...
Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.
Executives from the South Korean bioventure firm Oscotec talk to Scrip about the significance of the recent license agreement for a third-generation EGFR inhibitor by partner Yuhan, and extolled the company’s other core pipeline products, which include novel candidates for rheumatoid arthritis and cancer.
Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.